219 related articles for article (PubMed ID: 19041433)
1. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
3. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis.
Ooi LL; Zheng Y; Zhou H; Trivedi T; Conigrave AD; Seibel MJ; Dunstan CR
Bone; 2010 Oct; 47(4):795-803. PubMed ID: 20638491
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice.
Liu J; Xu K; Wen G; Guo H; Li S; Wu X; Dai R; Sheng Z; Liao E
Bone; 2008 May; 42(5):950-9. PubMed ID: 18337202
[TBL] [Abstract][Full Text] [Related]
6. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.
Tannehill-Gregg SH; Levine AL; Nadella MV; Iguchi H; Rosol TJ
Clin Exp Metastasis; 2006; 23(1):19-31. PubMed ID: 16715352
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Martin CK; Werbeck JL; Thudi NK; Lanigan LG; Wolfe TD; Toribio RE; Rosol TJ
Cancer Res; 2010 Nov; 70(21):8607-16. PubMed ID: 20959474
[TBL] [Abstract][Full Text] [Related]
8. Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating.
Greiner S; Kadow-Romacker A; Schmidmaier G; Wildemann B
J Biomed Mater Res A; 2009 Oct; 91(1):288-95. PubMed ID: 18980195
[TBL] [Abstract][Full Text] [Related]
9. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
11. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
13. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice.
Sheng ZF; Xu K; Ma YL; Liu JH; Dai RC; Zhang YH; Jiang YB; Liao EY
Osteoporos Int; 2009 Jan; 20(1):151-9. PubMed ID: 18496637
[TBL] [Abstract][Full Text] [Related]
16. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.
van der Pluijm G; Que I; Sijmons B; Buijs JT; Löwik CW; Wetterwald A; Thalmann GN; Papapoulos SE; Cecchini MG
Cancer Res; 2005 Sep; 65(17):7682-90. PubMed ID: 16140935
[TBL] [Abstract][Full Text] [Related]
17. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
18. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]